Close
Close
Treatment News

Genzyme rare-disease drug gets priority label

1.5
1.5 from 2 votes
Friday, December 13, 2013

Learn more about:

Clinical Trials

The FDA granted priority review status to Genzyme's experimental, all-oral Gaucher's disease treatment Cerdelga (eliglustat).

The FDA's priority label means the regulator will decide for or against the twice-a-day pill within six months.

The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher's disease.

Source: Medical Marketing and Media
1.5
1.5 from 2 votes
Free Newsletter
Related Videos
by Abidemi Uruejoma
98 views